-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$6.5021566.67% Upside
Pear Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Pear Therapeutics, Inc.?
Pear Therapeutics, Inc. has been rated by research analysts at Citigroup, Chardan Capital in the past 90 days.